[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Zoetis Inc Cl A (ZTS)

Zoetis Inc Cl A (ZTS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Could Zoetis Pipeline Promise Distract From a Companion Animal Business in Structural Decline?

Zoetis Inc. (ZTS) reports second-quarter 2026 earnings before market open on August 6, with analysts expecting $1.84 per share on revenue of approximately $2.5 billion. The central question: can the animal health leader stabilize after a brutal first quarter that saw shares plunge 25% on a rare earnings miss, or will macroeconomic headwinds and competitive pressures continue to weigh on profitability and investor confidence?

Zoetis is the world's largest producer of medicine and vaccinations for pets and livestock, operating across companion animal and livestock segments in both U.S. and international markets. The company reports Q2 2026 earnings before market open on August 6, with the...

Fundamentals

See More
  • Market Capitalization, $K 31,186,370
  • Shares Outstanding, K 419,228
  • Annual Sales, $ 9,467 M
  • Annual Income, $ 2,673 M
  • EBIT $ 3,435 M
  • EBITDA $ 3,922 M
  • 60-Month Beta 0.74
  • Price/Sales 3.37
  • Price/Cash Flow 10.05
  • Price/Book 9.89

Options Overview Details

View History
  • Implied Volatility 38.10% (-18.19%)
  • Historical Volatility 26.21%
  • IV Percentile 63%
  • IV Rank 45.38%
  • IV High 56.85% on 08/04/26
  • IV Low 22.52% on 08/12/25
  • Expected Move (DTE 15) 4.52 (6.10%)
  • Put/Call Vol Ratio 1.98
  • Today's Volume 4,689
  • Volume Avg (30-Day) 5,191
  • Put/Call OI Ratio 0.68
  • Today's Open Interest 167,065
  • Open Int (30-Day) 149,485
  • Expected Range 69.66 to 78.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.84
  • Number of Estimates 8
  • High Estimate $1.89
  • Low Estimate $1.77
  • Prior Year $1.76
  • Growth Rate Est. (year over year) +4.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
72.98 +3.83%
on 08/05/26
80.17 -5.48%
on 08/03/26
+0.36 (+0.47%)
since 07/06/26
3-Month
71.47 +6.03%
on 06/30/26
91.64 -17.31%
on 05/07/26
-35.44 (-31.87%)
since 05/06/26
52-Week
71.47 +6.03%
on 06/30/26
160.48 -52.78%
on 08/20/25
-70.72 (-48.28%)
since 08/06/25

Most Recent Stories

More News
Zoetis (NYSE:ZTS) Misses Q2 CY2026 Sales Expectations

Zoetis (NYSE:ZTS) Misses Q2 CY2026 Sales Expectations

ZTS : 76.36 (+2.65%)
Zoetis: Q2 Earnings Snapshot

Zoetis: Q2 Earnings Snapshot

ZTS : 76.36 (+2.65%)
Zoetis Appoints Jay Saccaro as Chief Financial Officer and Chief Operating Officer

Saccaro’s Appointment is Effective August 17, 2026; Wetteny Joseph to Serve as a Special Advisor to the CEO on Financial Matters Until Early 2027

ZTS : 76.36 (+2.65%)
Zoetis Announces Second Quarter 2026 Results

Revenue Flat at $2.5 Billion and Net Income of $691 Million, or $1.65 per Diluted Share, Decreasing 5% and Increasing 1%, Respectively, on a Reported Basis ...

ZTS : 76.36 (+2.65%)
Could Zoetis Pipeline Promise Distract From a Companion Animal Business in Structural Decline?

Barchart Research What to Expect from ZTS Earnings ZTS Generated August 5, 2026 Current Price $74.39 EPS Estimate $$1.84 Consensus Rating Moderate Buy Average Move 7.68% Could Zoetis Pipeline Promise Distract...

ZTS : 76.36 (+2.65%)
Zoetis (ZTS) Reports Q2: Everything You Need To Know Ahead Of Earnings

Zoetis (ZTS) Reports Q2: Everything You Need To Know Ahead Of Earnings

ZTS : 76.36 (+2.65%)
The Bull Case for Zoetis Stock as Michael Burry Doubles Down

Michael Burry has chosen to believe in Zoetis’ growth story by increasing his position.

XLV : 163.72 (-0.27%)
ZTS : 76.36 (+2.65%)
Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES , July 24, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP  announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against...

ZTS : 76.36 (+2.65%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zoetis Inc. of Class Action Lawsuit and Upcoming Deadlines - ZTS

NEW YORK , July 23, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Zoetis Inc. ("Zoetis" or the "Company") (NYSE: ZTS).   Such investors are...

ZTS : 76.36 (+2.65%)
3 Healthcare Stocks with Competitive Advantages

3 Healthcare Stocks with Competitive Advantages

VRTX : 483.52 (-0.27%)
ZTS : 76.36 (+2.65%)
ALHC : 13.63 (-0.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Zoetis Inc. is a leader in the animal health space with a focus on both livestock and companion animals in seven major product categories: vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics. Zoetis has a diversified...

See More

Key Turning Points

3rd Resistance Point 80.04
2nd Resistance Point 78.34
1st Resistance Point 76.37
Last Price 76.36
1st Support Level 72.70
2nd Support Level 71.00
3rd Support Level 69.03

See More

52-Week High 160.48
Fibonacci 61.8% 126.48
Fibonacci 50% 115.97
Fibonacci 38.2% 105.47
Last Price 76.36
52-Week Low 71.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.